Aug 16, 2023 / 10:00PM GMT
John Newton Sourbeer - UBS Investment Bank, Research Division - Equity Research Associate
So thanks for -- welcome to the UBS 2023 conference here. I'm John Sourbeer, UBS's life science analyst. Happy to host the fireside today with West Pharmaceuticals. Joining me is CEO and President, Eric Green; and VP of Investor Relations, Quintin Lai. Thanks for attending here.
Eric M. Green - West Pharmaceutical Services, Inc. - Chair, President & CEO
Yes, John, thanks for having us. It's been a really good day here at UBS. So thank you.
Questions and Answers:
John Newton Sourbeer - UBS Investment Bank, Research Division - Equity Research AssociateGreat. So maybe start off here, high-level question. I know you guys reported earnings a couple of weeks ago, but on the demand environment, the company continues to see strong demand really across this proprietary product segment and the broader portfolio despite macro headwinds seen by peers and others within biologics or [larger] biopharma life science tools. So I guess